PET Imaging Study Identifies Brain Metabolism Patterns Predictive of Alzheimer's Treatment Efficacy

In a significant advance presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, researchers showcased a study demonstrating the potential of PET imaging in predicting the effectiveness of Alzheimer's disease therapies. The study, awarded the prestigious Henry N. Wagner, Jr. Abstract of the Year, indicated that specific patterns of brain metabolism detectable through PET imaging could help identify patients most likely to benefit from Alzheimer's treatments.

Every year, SNMMI honors an abstract that highlights groundbreaking innovations in nuclear medicine and molecular imaging. This year's award-winning study was selected from nearly 1,500 submissions, focusing on the crucial role of PET imaging in managing Alzheimer's disease.

Alzheimer's disease is characterized by the presence of amyloid plaques in the brain. The U.S. Food and Drug Administration (FDA) has recently approved two anti-amyloid therapies targeting these plaques. Despite their general efficacy, there is significant variability in treatment outcomes among individuals. According to Dr. Amanda Rose Nguyen from the David Geffen School of Medicine at the University of California, Los Angeles, "Many patients who meet the clinical diagnosis criteria for Alzheimer's disease may have other neurological conditions contributing to cognitive impairment." This variability could explain the inconsistent success rates observed with anti-amyloid therapies.

Given the proven accuracy of 18F-FDG PET scans in diagnosing Alzheimer's disease, even at its early stages, the study aimed to assess how brain metabolic data from these scans relate to clinical outcomes in patients undergoing anti-amyloid therapy. The researchers analyzed a cohort of 124 patients reviewed by a university committee for potential amyloid immunotherapy. The study compared brain 18F-FDG PET data, treatment decisions, and cognitive performance before and after one year of therapy.

The findings revealed distinct brain metabolism patterns indicative of Alzheimer's disease, Lewy body disease, Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), or frontotemporal lobar degeneration. Patients showing Alzheimer's disease metabolism patterns demonstrated improved cognitive performance scores, while those with non-Alzheimer's patterns experienced significant cognitive decline. Dr. Nguyen commented, "This work demonstrates that 18F-FDG PET is an important tool in the diagnosis of dementia. Physicians can use this data to provide more personalized care, prescribing therapy to those most likely to benefit."

Dr. Nguyen further anticipates that expanded analyses later in the year will enhance the predictive capabilities of brain metabolism patterns. Until then, she advises clinicians to use comprehensive neuroimaging to guide individualized treatment decisions effectively.

This study underscores the potential of PET imaging to refine treatment strategies for Alzheimer's disease, offering hope for more targeted and effective interventions for patients.